Vaccine, influenza


Concise Prescribing Info
Indications/Uses
Active immunisation against influenza.
Dosage/Direction for Use
Adult : IM/SC As surface antigen, inactivated or split virion, inactivated influenza vaccine: 0.5 mL as 1 dose per season. Intradermal As inactivated quadrivalent influenza vaccine: 9 mcg as 1 dose per season. Nasal As live, attenuated quadrivalent influenza vaccine: 0.2 mL as 1 dose per season.
Dosage Details
Intradermal
Active immunisation against influenza
Adult: 18-64 years As inactivated quadrivalent influenza vaccine: 9 mcg as 1 dose per season.

Nasal
Active immunisation against influenza
Adult: As live, attenuated quadrivalent influenza vaccine: ≤49 years 0.2 mL (0.1 mL in each nostril) as 1 dose per season.
Child: As live, attenuated tetravalent influenza vaccine: 2-17 years 0.2 mL (0.1 mL in each nostril), a second dose is given after at least 4 weeks in children who have not been vaccinated previously. As live, attenuated quadrivalent influenza vaccine: 2-8 years 0.2 mL (0.1 in each nostril), a second dose is given after at least 4 weeks in children who have not been vaccinated previously; 9 years Same as adult dose.

Parenteral
Active immunisation against influenza
Adult: As surface antigen, inactivated or split virion, inactivated influenza vaccine: 0.5 mL as 1 dose per season via IM or deep SC inj.
Child: As surface antigen, inactivated influenza vaccine: 6-35 months 0.25 or 0.5 mL as 1 dose per season, in accordance with existing national recommendations; ≥3 years 0.5 mL as 1 dose per season. Repeat dose at least 4 weeks later if child was not previously vaccinated. As split virion, inactivated influenza vaccine: ≥5 years 0.5 mL as 1 dose per season; a 2nd dose should be given after at least 4 weeks in children <9 years who have not been previously vaccinated.
Contraindications
Hypersensitivity to any influenza vaccine, egg or chicken proteins. Severely immunosuppressed patients (e.g. HIV patients). Concomitant salicylate therapy (nasal).
Special Precautions
Patient with asthma, acute illness, recurrent or active wheezing (children <5 years), CV disorders, personal or family history of febrile convulsions, history of Guillain-Barre syndrome; nasal congestion (nasal). Postpone vaccination in patients with active infection or acute febrile illness. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Syncope, hyperventilation, stress-related reactions, paraesthesia, transient visual disturbance, tonic-clonic limb movements.
Cardiac disorders: Chest tightness.
Gastrointestinal disorders: Sore throat, abdominal pain, gastroenteritis, nausea, vomiting.
General disorders and administration site conditions: Irritability, lethargy, fatigue, weakness, malaise, diaphoresis; injection site reactions (e.g. erythema, bruising, swelling).
Infections and infestations: Infection, varicella.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Myalgia, chills, arthralgia, back pain.
Nervous system disorders: Headache, migraine.
Psychiatric disorders: Drowsiness.
Respiratory, thoracic and mediastinal disorders: Cough, nasal congestion, rhinorrhoea.
Skin and subcutaneous tissue disorders: Ecchymosis.
Vascular disorders: Hypertension.
Potentially Fatal: Severe hypersensitivity (e.g. anaphylaxis).
Nasal/Parenteral: C; Intradermal: B
MonitoringParameters
Monitor for signs of anaphylaxis.
Drug Interactions
Decreased immunological response with immunosuppressants.
Potentially Fatal: Concomitant treatment with salicylates (e.g. aspirin) may lead to Reye’s syndrome (nasal).
Lab Interference
False-positive results in serology tests using enzyme-linked immunosorbent assays (ELISAs) method to detect antibodies to HIV-1, HTLV-1 and hepatitis C virus. May cause positive result on the rapid influenza diagnostic test for the 7 days after vaccine administration (nasal). May diminish diagnostic effect of tuberculin tests.
Action
Description: Influenza virus vaccine promotes immunity to influenza virus by inducing specific antibody production.
Synonym: flu vaccine.
Onset: Within 2 weeks of vaccination.
Duration: ≥6-8 months.
Pharmacokinetics:
Distribution: Nasal: Distributed in the nasal cavity (approx 90%), stomach (approx 3%), brain (approx 2%), and lungs (0.4%).
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
ATC Classification
J07BB - Influenza vaccines ; Used for active immunizations.
References
Anon. Influenza Virus Vaccine (Inactivated). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/06/2018.

Anon. Influenza Virus Vaccine (Live/Attenuated). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/06/2018.

Buckingham R (ed). Influenza Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/06/2018.

Flumist Quadrivalent Intranasal Spray (MedImmune, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 26/06/2018.

Fluzone Intradermal Quadrivalent (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 26/06/2018.

Joint Formulary Committee. Influenza Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/06/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, influenza from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Agrippal S1
  • Inflexal V
  • Vaxigrip
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in